Overview

Study of TP-04 in Participants With Papulopustular Rosacea

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).
Phase:
Phase 2
Details
Lead Sponsor:
Tarsus Pharmaceuticals, Inc.